Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UCSF

Sites in San Francisco, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1396
Shown on this page
12
Current sort
Recently updated
Campus scope
UCSF, San Francisco, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UCSF, San Francisco, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1177–1188 of 1,396 matching trials with a site at UCSF, San Francisco, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1 Interventional

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

NCT05239143
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer
Interventions
P-MUC1C-ALLO1 CAR-T cells, Rimiducid
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2039
U.S. locations
14
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Nov 5, 2026, 12:33 AM EST
Recruiting Phase 3 Interventional

Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

NCT05026749
Status at this site: Recruiting
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
AZM Group, Control Group
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
3 Days to 2 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Nov 5, 2026, 12:33 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

NCT04478279
Site status not listed — check the official record
View directory record Official record
Conditions
Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Interventions
ST101, Temozolomide, Radiation
Drug · Radiation
Lead sponsor
Sapience Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Nov 5, 2026, 12:33 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

NCT03933735
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
TNB-383B
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
10
States / cities
San Francisco, California • New Orleans, Louisiana • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 5, 2026, 12:33 AM EST
Active, not recruiting No phase listed Observational

Vincristine Pharmacokinetics in Infants

NCT05359237
Site status not listed — check the official record
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Vincristine
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 12 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 5, 2026, 12:33 AM EST
Active, not recruiting No phase listed Observational

Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy

NCT05361070
Site status not listed — check the official record
View directory record Official record
Conditions
Neonatal Seizure, Hypoxic-Ischemic Encephalopathy, Stroke, Intracranial Hemorrhage, Epilepsy, Gene Abnormality
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Nov 5, 2026, 12:33 AM EST
Active, not recruiting No phase listed Observational

Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F

NCT04765345
Site status not listed — check the official record
View directory record Official record
Conditions
Retinal Degeneration, Retinitis Pigmentosa, Eye Diseases, Hereditary
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
8 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 5, 2026, 12:33 AM EST
Recruiting No phase listed Observational

A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer

NCT03193515
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 5, 2026, 12:33 AM EST
Active, not recruiting Phase 2 Interventional

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

NCT04740476
Site status not listed — check the official record
View directory record Official record
Conditions
Dravet Syndrome
Interventions
zorevunersen (STK-001)
Drug
Lead sponsor
Stoke Therapeutics, Inc
Industry
Eligibility
30 Months and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
17
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 5, 2026, 12:33 AM EST
Recruiting Not applicable Interventional

Preschool Hearing Screening

NCT06058767
Status at this site: Recruiting
View directory record Official record
Conditions
Hearing Loss, Hearing Disorders in Children, Hearing Loss, Sensorineural, Hearing Loss, Conductive, Hearing Loss, Unilateral, Hearing Loss, Noise-Induced, Hearing Loss, Mixed, Hearing Loss, Bilateral
Interventions
Otoacoustic Emissions Testing, Pure Tone Audiometry
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 6 Years
Enrollment
13,764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Nov 5, 2026, 12:33 AM EST
Active, not recruiting Not applicable Interventional

Sleep for Stroke Management and Recovery Trial

NCT03812653
Site status not listed — check the official record
View directory record Official record
Conditions
Ischemic Stroke, Sleep Apnea, Sleep Apnea, Obstructive, Stroke, CPAP, Telemedicine, Home Sleep Apnea Test, Randomized Clinical Trial, Multicenter Trial
Interventions
CPAP
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
3,062 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
116
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Nov 5, 2026, 12:33 AM EST
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection

NCT01651403
Site status not listed — check the official record
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Tenofovir DF, TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 11 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
5
States / cities
Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Nov 5, 2026, 12:33 AM EST

About this UCSF institution page

What this page lists
ClinicalTrials.gov records that list UCSF in San Francisco, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by University of California, San Francisco at any site, browse by condition, or browse by U.S. city.